Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526585 | 0.82 | LTA4H (0.51) | LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL529656 | 0.80 | KDM4E (0.42) | LTA4HBRD4SMN1; SMN2 | |
| SCHEMBL2491004 | 0.80 | PDE3B (0.46) | LTA4HPDE3BPDE3AP2RY12MAPT | |
| SCHEMBL525916 | 0.76 | PDE3B (0.39) | LTA4HBRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL525935 | 0.75 | PDE3B (0.39) | LTA4HBRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL526828 | 0.74 | LTA4H (0.57) | LTA4HBRD4PDE3BPDE3AP2RY12 | |
| SCHEMBL2491624 | 0.74 | PDE4A (0.38) | BRD4PDE3BPDE3AP2RY12SMN1; SMN2 | |
| SCHEMBL2492660 | 0.72 | DYRK1A (0.46) | LTA4HPDE3BPDE3AP2RY12MAPT | |
| SCHEMBL8636181 | 0.70 | CYP1A2 (0.59) | LTA4H | |
| SCHEMBL14973568 | 0.70 | KDM4E (0.45) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| EP-2598507-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | LTA4H 4377/4885BRD4 2688/4885PDE3B 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.